Business Context and Reporting Period
Kura Oncology, Inc. filed a Form 8-K on August 12, 2026, to announce financial results for the second quarter ended June 30, 2026, alongside a corporate update.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing text does not provide data to compare current period results against prior comparable periods. Specific material changes are detailed in the referenced Exhibit 99.1.
Guidance, Outlook, and Risks
The Company issued a corporate update as part of this announcement. However, the filing text does not contain specific details regarding future guidance, management commentary, risks, contingencies, or unusual items. This information is located in the attached press release (Exhibit 99.1).
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 12, 2026) for specific Q2 2026 financial figures.
- Verify the Company's cash runway and burn rate as disclosed in the press release.
- Confirm details of the corporate update and any changes to clinical trial timelines or milestones.
- Check for any new risk factors or contingencies mentioned in the full press release text.